Clinical trials: Advanced Solid Tumors, Adult
Adult Solid Tumor, Diffuse Large B Cell Lymphoma
A Phase I Trial of AZD3965 in Patients With Advanced Cancer
The main aims of this clinical study are to find out the maximum dose that can be given safely to patients, the potential side effects of the drug and how they can be managed and what happens to AZD3965 inside the body.
- Conditions
- Adult Solid Tumor, Diffuse Large B Cell Lymphoma, Burkitt Lymphoma
- Trial name
- NCT01791595
- Testing
- AZD3965
- Where
- 7 sites in United Kingdom
- Volunteers
- 53 people
- Sponsor
- Cancer Research UK
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Advanced Solid Tumors
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib.
- Trial name
- NCT05949632
- Testing
- INCB099280, axitinib
- Where
- 6 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Advanced Non-small Cell Lung Cancer
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
This is a Phase I/II, multi-center, open-label study, composed with a Phase I part (dose-escalation phase) followed by a Phase II part (expansion phase).
- Trial name
- NCT02108964
- Testing
- EGF816
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Malignant Solid Neoplasm, Cholangiocarcinoma
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other…
- Conditions
- Advanced Malignant Solid Neoplasm, Cholangiocarcinoma, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
- Trial name
- NCT04233567
- Testing
- Infigratinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sameek Roychowdhury
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Solid Tumours
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
This is a phase Ib, open-label, multicentre study of AZD1775 administered orally in monotherapy and in combination with carboplatin and paclitaxel to Asian patients with advanced solid tumours.
- Trial name
- NCT02341456
- Testing
- AZD1775, Paclitaxel, carboplatin
- Where
- 7 sites in Australia, Japan and 1 more
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Brain and Central Nervous System Tumors, Melanoma
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
RATIONALE: Drugs used in chemotherapy, temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
- Trial name
- NCT00512798
- Testing
- PS-341 (VELCADE), temozolomide, immunoenzyme technique
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neoplasms
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm.
- Trial name
- NCT03416335
- Testing
- DSP-0509, DSP-0509, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sumitomo Pharma America, Inc.
Neoplasm
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
This clinical study evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of dalotuzumab (MK-0646) in participants with relapsed or refractory locally advanced or metastatic solid tumors using once weekly and…
- Trial name
- NCT00694356
- Testing
- Dalotuzumab
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390429
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of California, Davis
Solid Neoplasms
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when…
- Trial name
- NCT03364049
- Testing
- MK-7162, Pembrolizumab
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Adult Solid Tumor
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in…
- Trial name
- NCT05147272
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 67 people
- Sponsor
- Debiopharm International SA
Unspecified Adult Solid Tumor, Protocol Specific
Benzoylphenylurea in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of benzoylphenylurea in treating patients who have advanced…
- Trial name
- NCT00016354
- Testing
- benzoylphenylurea
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasms, Neoplasm Metastasis
A Study of AK-01 (LY3295668) in Solid Tumors
This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or…
- Conditions
- Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT03092934
- Testing
- LY3295668
- Where
- 3 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Lung Cancer
Abraxane and Alimta in Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00470548
- Testing
- Abraxane, Alimta
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of California, Davis
Adult Solid Tumor
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
The purpose of the study is to evaluate safety and tolerability and determine a recommended Phase 2 dose for TRC105 when added to standard dose bevacizumab in patients with advanced solid tumors for which bevacizumab is indicated.
- Trial name
- NCT01332721
- Testing
- TRC105 and Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Solid Tumors
A Study of TAK-103 in Adult With Solid Tumors
In this study, people with mesothelin-expressing advanced or metastatic solid tumors will receive TAK-103 with their white blood cells.
- Trial name
- NCT05164666
- Testing
- TAK-103
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Takeda
Solid Tumor, Lymphoma
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when…
- Trial name
- NCT03249792
- Testing
- MK-2118 (IT), MK-2118 (SC), Pembrolizumab
- Where
- 8 sites in United States, Israel
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC